• Freeman T, Washington MK, Fan KH, Shyr Y, Beauchamp RD, Zijlstra A. Correlation of elevated ALCAM shedding with patient outcome in colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Oct 20;30(30_suppl). 46 p. PMID: 28142499 [PubMed].


46 Background: ALCAM (Activated Leukocyte Cell Adhesion Molecule) is a cell-cell adhesion protein that has been highlighted as a putative biomarker for the progression of many cancers, including colorectal cancer (CRC). Current prognosis for CRC patients predominantly rely on pathologic staging classification. Although TNM staging successfully stratifies high-risk patients, there is significant variability in the rate of disease progression within each stage. Previous studies evaluating ALCAM as a biomarker for predicting colorectal cancer patient survival have published conflicting and inconclusive results. The aim of this present study was to investigate the prognostic value of ALCAM shedding, quantified using a dual stain that detects both the extracellular and the intracellular domains in formalin-fixed tissue, in colorectal patients.